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Abstract 17 
Background: Human populations native to high altitude exhibit numerous genetic adaptations to hypobaric hypoxia. Among Tibetan 18 
Plateau peoples, these include increased vasodilation and uncoupling of erythropoiesis from hypoxia. 19 
Objective/Methods: We tested the hypothesis that these high-altitude adaptations reduce risk for hypertension and diabetes-20 
associated anemia among the Mosuo, a Tibetan-descended population in the mountains of Southwest China that is experiencing rapid 21 
economic change and increased chronic disease risk.  22 
Results: Hypertension was substantially less common among Mosuo than low-altitude Han populations, and models fit to the Han 23 
predicted higher probability of hypertension than models fit to the Mosuo. Diabetes was positively associated with anemia among the 24 
Han, but not the Mosuo.  25 
Conclusion: The Mosuo have lower risk for hypertension and diabetes-associated anemia than the Han, supporting the hypothesis that 26 
high-altitude adaptations affecting blood and circulation intersect with chronic disease processes to lower risk for these outcomes. As 27 
chronic diseases continue to grow as global health concerns, it is important to investigate how they may be affected by local genetic 28 
adaptations.   29 
Keywords: High-altitude adaptation, hypertension, erythropoiesis, anemia, diabetes 30 
 31 
Research Highlights:  32 
• Some high-altitude adaptations overlap with mechanisms of chronic diseases, such as hypertension, which may affect risk for 33 
these diseases. 34 
• Hypertension and diabetes-associated anemia are less common among the Mosuo, a Tibetan-descended population, than the 35 
Han. 36 
• As chronic diseases continue to grow as global health concerns, it is important to investigate how risk may be affected by 37 
genetic adaptation to the local environment. 38 
 39 
Tweetable Summary: Humans adapted to high altitude may have lower risk for some chronic diseases.  40 
Introduction 41 
Low oxygen pressure at altitudes over ~2 km induces hypoxic stress, with cascading consequences for human performance and 42 
evolution. Populations of the Tibetan Plateau have been living at altitudes of up to ~5400 m for thousands of years (Beall, 2007), and 43 
exhibit a suite of characteristics that appear to fully mitigate this stress: whereas sojourners to high altitude experience a ~10-20% 44 
deficit in maximal oxygen uptake, Tibetans at high altitude show no deficit (Beall, 2007).  45 
Understanding of Tibetan Plateau populations’ adaptations to high altitude is increasing rapidly, particularly with regard to 46 
their genetic bases (Beall et al., 2010; Bigham et al., 2010; Bigham & Lee, 2014; Erzurum et al., 2007; Gilbert-Kawai et al., 2017; 47 
Guo, He, & Cui, 2017; He et al., 2018; Peng et al., 2010; Simonson et al., 2010; Yi et al., 2010; Zheng, He, & Cui, 2017). Some of 48 
these adaptations overlap with mechanisms of multiple chronic diseases, meaning that chronic disease etiology, risk, and 49 
complications are likely to manifest differently in human populations genetically adapted to high altitude. This remains an under-50 
researched aspect of high altitude adaptation, and one that is becoming increasingly urgent as the global burden of chronic disease 51 
continues to grow. 52 
We investigated the intersection of high-altitude adaptation and chronic disease among the Mosuo ethnic group, close relatives 53 
of Tibetans (Jeong et al., 2017; Lu et al., 2012; Wen et al., 2004; Yang et al., 2004) living in the Hengduan Mountains southeast of the 54 
Tibetan Plateau, at ~2600 m altitude. Population-genetic research suggests that the Mosuo are closely related to a group of Tibetan 55 
Plateau peoples who descended from a single ancestral Himalayan population that carried high-altitude adapted alleles at a suite of 56 
key functional genes (Arciero et al., 2018; Jeong et al., 2017; Lu et al., 2012; Wen et al., 2004; Yang et al., 2004). Cultural and 57 
historical work suggests that the Mosuo have been residing at high elevation for ~1500 years (Shih, 1994), suggesting that ancestral 58 
variation that was advantageous at altitude would have been maintained. 59 
Many Mosuo communities are undergoing a rapid process of market integration associated principally with increasing tourism 60 
around the Lugu Lake area of Yunnan (Blumenfield, Sum, Shenk, & Mattison, 2018; Mattison, 2010). Chronic diseases like type 2 61 
diabetes and hypertension have increased strikingly among populations undergoing integration into markets, due to changes in diets, 62 
physical activity, and social structure (Chan et al., 2009; Kuhnlein & Receveur, 1996). The Mosuo’s recent Tibetan ancestry and rapid 63 
market integration bring together high-altitude adaptation and high chronic disease risk, allowing us to observe how the two interact.  64 
Tibetan Plateau adaptations to hypoxia enhance blood flow to tissues via high nitric oxide (NO) production, vasodilation, 65 
reduced vascular resistance, and denser capillary networks (Beall, Laskowski, & Erzurum, 2012; Bigham & Lee, 2014; Erzurum et al., 66 
2007). This unique vascular physiology augments oxygen delivery to compensate for reduced arterial blood oxygen content (Beall, 67 
2007; Bigham & Lee, 2014). It also seems likely to lower susceptibility to chronic hypertension (elevated arterial blood pressures), as 68 
hypertension may be attributable to underproduction of vasodilators such as NO in the endothelium, and subsequent smooth muscle 69 
cell contraction and arteriole wall thickening (Beevers, Lip, & O’Brien, 2001).  70 
Previous research into Tibetans’ risk for hypertension, however, is ambiguous and poorly suited to test this hypothesis. Blood 71 
pressures generally increase with altitude due to hypoxic stress; this has been observed among sojourners (Calbet, 2003; Luks, 2009), 72 
those raised at altitude (Aryal, Weatherall, Bhatta, & Mann, 2018; Norboo et al., 2015), and Tibetans (Aryal, Weatherall, Bhatta, & 73 
Mann, 2016; Mingji, Onakpoya, Perera, Ward, & Heneghan, 2015). Both lower rates of hypertension (Norboo et al., 2015) and higher 74 
rates of hypertension (Sun, 1986) have been reported among Tibetans, compared to Han or other ethnic groups at similar altitudes—75 
this likely reflects differences in subsistence, diet, and lifestyle that confound direct comparisons between Tibetan Plateau and lowland 76 
populations residing at altitude. We resolve this by comparing Mosuo risk for hypertension to that predicted from models fit to Han 77 
with similar overall lifestyle characteristics.  78 
Tibetan Plateau adaptations to high altitude also include a blunted erythropoietic response to hypoxia: in the presence of 79 
physiological changes to enhance oxygen delivery to tissues in the presence of reduced arterial blood oxygen content, natural selection 80 
favored changes to the hypoxia-inducible factor (HIF) pathway that uncoupled erythropoiesis from hypoxia sensing, allowing Tibetans 81 
to avoid erythrocytosis and blood hyperviscosity (Beall et al., 2010; Bigham et al., 2010; Peng et al., 2010; Simonson et al., 2010; Yi 82 
et al., 2010). Thus, whereas elevated blood hemoglobin concentration (Hb) is typical of lowland-native sojourners to high altitude, 83 
Tibetan Plateau populations exhibit only moderately elevated Hb (Beall, 2007; Bigham & Lee, 2014). This blunted erythropoiesis may 84 
lower risk for anemia associated with chronic disease, particularly diabetes.  85 
Diabetes is defined by persistent elevated blood glucose, and caused by impaired production of, or sensitivity to, the hormone 86 
insulin, which promotes tissue absorption of glucose. Although not consistently emphasized in discussions of diabetes complications, 87 
anemia is very common among people with both type 1 and type 2 diabetes (El-Achkar et al., 2005; Goldhaber, Ness-Abramof, & 88 
Ellis, 2009; Thomas, MacIsaac, Tsalamandris, Power, & Jerums, 2003; Thomas et al., 2004). Multiple pathways may link diabetes and 89 
anemia, including inflammation, autoimmunity, and micronutrient deficiency. However, one pathway unique to diabetes has 90 
repeatedly been implicated: the impaired ability to correct insipient anemia via the homeostatic kidney erythropoietin (EPO) response. 91 
HIF-pathway hypoxia sensing in normally-functioning kidneys maintains oxygen homeostasis by increasing EPO production by 92 
peritubular fibroblasts in response to hypoxia and vasoconstriction (Fisher, 2003; McGill & Bell, 2006). Diabetic kidney damage to 93 
the peritubular fibroblasts can result in fibrosis (McGill & Bell, 2006), leading to failed EPO elevation among diabetics (McGill & 94 
Bell, 2006; Thomas, 2006). This failure is likely attributable to impaired sensitivity to hypoxia, rather than EPO secretory capacity 95 
(Bosman et al., 2002; Fisher, 2003; Thomas, 2006). Because erythropoiesis in the Tibetan-type adaptation to high altitude is already 96 
decoupled from the hypoxia-sensing HIF pathway, risk for diabetes-associated anemia may be lower among Tibetan-descended 97 
populations.  98 
We tested the predictions that Tibetan-type high-altitude adaptations lower risk for hypertension and diabetes-associated 99 
anemia among the Mosuo. We collected data among the Mosuo in Yunnan province, and accessed data from the China Health and 100 
Nutrition Survey (CHNS) for two Han comparison groups: 1) all Han included in the CHNS data; and 2) a sub-sample of the first 101 
comparison group limited to Han from rural Hunan, which is southern and inland, like the Mosuo homeland in Yunnan and Sichuan, 102 
but lower in altitude (~100-800 m), and offers a larger sample of Han in CHNS than other nearby provinces. Because rates of 103 
hypertension may differ across ethnic groups due to disparate lifestyles, we compared models of hypertension from the Mosuo and 104 
rural Hunan Han samples, who are broadly comparable in terms of diet and subsistence, to test the hypothesis that Mosuo have overall 105 
lower risk for hypertension, given the same risk factors. For the diabetes-associated anemia outcome, we compared models of anemia 106 
across the three samples to test the hypothesis that diabetes is a risk factor for anemia among the Han, but not the Mosuo (Table 1). 107 
 108 
Materials & Methods 109 
Study setting and design: Risk factors for hypertension and associations between diabetes and anemia among Han Chinese were 110 
assessed using data from the China Health and Nutrition Survey (http://www.cpc.unc.edu/projects/china). CHNS used random cluster 111 
sampling to generate a representative sample of residents of participating Chinese provinces; in 2009 (the year for which biomarker 112 
data were available), this included 217 communities from 9 provinces (Guangxi, Guizhou, Heilongjiang, Henan, Hubei, Hunan, 113 
Jiangsu, Liaoning, Shandong).  114 
Risk factors for hypertension and associations between diabetes and anemia among the Mosuo were assessed as part of a larger 115 
survey of the Mosuo investigating the impact of rapid market integration on wealth, health, and inequality. Rapid market integration is 116 
occurring among some Mosuo communities due to increasing tourism around Lugu Lake in Yunnan Province. Communities were 117 
selected to include those with high, moderate, and low levels of participation in the tourism economy. The median altitude of 118 
residence for our study participants was 2638 m (range, 1515 to 3050 m). 119 
The demographic survey portion of the Mosuo study occurred in 2017. A sample of survey participants were subsequently 120 
invited to participate in a second round of data collection (including diabetes and anemia screenings) which was carried out in the 121 
summers of 2017 and 2018. Individual participants were not selected at random; instead, subsets of communities from the larger 122 
survey were targeted to ensure representation of communities with varying degrees of access to markets. All adult participants in those 123 
communities were invited, and all of those who volunteered were included in the subsample for this study. 124 
Biomarker selection: Aspects of health (inflammation, diabetes, iron deficiency, and anemia) were described among this subsample 125 
using biomarkers. Biomarkers for these health outcomes were selected to be measurable, when possible, with field-friendly point-of-126 
care test (POCT) devices, and, when this was not possible, to be measurable in dried blood spot (DBS) specimens. Biomarkers were 127 
also selected for interpretability in a population with a high burden of infectious disease (e.g., robustness of the iron nutrition 128 
biomarker to changes in inflammation), and for practicality in population-based research (e.g., minimal diurnal variation in all 129 
biomarkers, minimal pre-test preparation requirements for participants). 130 
Diabetes was characterized with glycated hemoglobin (HbA1c). HbA1c has been validated against blood glucose measures as 131 
gold standards (World Health Organization, 2011b); it was selected for use in this project to meet the practical limitations of 132 
population-based research, as it does not require research participants to fast prior to participation, and is less variable over short time 133 
scales than fasting plasma glucose or oral glucose tolerance tests (Sacks, 2011). Limitations of HbA1c include artificially low values 134 
for individuals with elevated erythrocyte turnover (e.g., due to hemolytic disease, hemoglobinopathy, or recent acute blood loss), and 135 
artificially high values for individuals with iron deficiency (with or without anemia) (English et al., 2015; Sacks, 2011). HbA1c 136 
introduces possible misclassification of diabetes, if erythropoiesis or erythrocyte lifespan were abnormal among Mosuo participants; 137 
this is unlikely, as elevated erythropoiesis is not part of the Tibetan pattern of adaptation to high altitude (Beall, 2007; Bigham & Lee, 138 
2014). Further, iron deficiency can result in artificially high HbA1c; this increase is significant, but small enough that it is unlikely to 139 
significantly overestimate rates of diabetes (Kim, Bullard, Herman, & Beckles, 2010; Sacks, 2011). We addressed this concern via 140 
statistical control for iron deficiency.  141 
Inflammation, a common predictor of chronic disease, was described with C-reactive protein (CRP), a stable, commonly-used, 142 
and easy to measure pro-inflammatory acute phase reactant. Iron deficiency was described with soluble transferrin receptor (sTfR), 143 
which, unlike many other biomarkers of iron status, is unaffected by inflammation and the acute phase response, enhancing its 144 
interpretability in settings with a high infectious disease burden, and is measurable in DBS (McDade & Shell-Duncan, 2002; World 145 
Health Organization, 2014). Anemia was described with Hb (World Health Organization, 2011a).  146 
Anthropometry: At the time of participation in the demographic survey of the Mosuo, each participant’s height was measured with a 147 
stadiometer (Seca 213) and weight with a digital scale (Tanita BF522W).  148 
Point of care testing: At the time of participation in the demographic survey of the Mosuo, blood pressures were estimated in 149 
duplicate using a portable upper arm blood pressure monitor (Omron HEM-BP785N), with the participant in a seated position after a 150 
period of rest. Coefficients of variation (CVs) for systolic and diastolic blood pressures were 3.5% and 5.4%, respectively. At the time 151 
of screening for diabetes and anemia, capillary whole blood was collected via finger stick with a sterile safety lancet. Blood specimens 152 
were immediately evaluated for HbA1c with the A1CNOW POCT (PTS Diagnostics) and Hb with a hemoglobinometer (HemoCue 153 
201+).  154 
Laboratory evaluation of biomarkers: After POCT, additional drops of whole blood were allowed to fall freely onto a filter paper card 155 
(Whatman #903) for DBS specimens. DBS were allowed to dry for up to 24h and were then frozen. Specimens were transported to the 156 
MOE Key Laboratory for Contemporary Anthropology at Fudan University and evaluated for CRP (BioCheck BC-1119) and soluble 157 
transferrin receptor (sTfR; Ramco TFC-94) using commercially available kits modified for use with DBS specimens: One 1/8 inch 158 
disc of DBS specimen was removed with a hole punch, combined with the specimen dilution buffer provided with each kit (125 μl for 159 
sTfR; 150 μl for CRP), and allowed to soak overnight at 4°C. The resulting eluent was assayed without further dilution; dilution was 160 
calculated as 1.5 μl serum equivalent (Mei, Alexander, Adam, & Hannon, 2001) per volume of dilution buffer. Specimens with 161 
unquantifiably high values were re-evaluated at higher dilutions as needed. Inter-assay CVs for sTfR were 14.1% at high and 11.7% at 162 
low concentrations; intra-assay CVs were 9.2% for CRP and 4.3% for sTfR.  163 
CHNS data access: CHNS datasets (“Biomarkers,” “Physical exam,” and “Survey”) were downloaded from the study website. 164 
Datasets were merged by individual id (IDIND) and data from the 2009 wave (the year for which biomarker information is available) 165 
were retained. 166 
Data analysis: Systolic and diastolic pressures were averaged across two estimates; when only one measurement of blood pressures 167 
was made, the single estimate was used. Blood pressures categories were defined as normal (average systolic < 120 mmHg and 168 
average diastolic < 80 mmHg), elevated (120 ≤ systolic < 130 mmHg and diastolic < 80 mmHg), stage 1 hypertension (130 ≤ systolic 169 
< 140 mmHg or 80 mmHg ≤ diastolic < 90 mmHg), and stage 2 hypertension (systolic ≥ 140 mmHg or diastolic ≥ 90 mmHg); for 170 
binary comparisons, hypertension was considered absent for normal or elevated blood pressures and present for stage 1 and stage 2 171 
hypertension (Whelton et al., 2017). Diabetes was defined as a reported physician’s diagnosis of diabetes or HbA1c ≥ 6.5% (World 172 
Health Organization, 2011b); no distinction was made between types 1 and 2 diabetes. Anemia was defined according to WHO 173 
standards (World Health Organization, 2011a) both with (as Hb < 13.3 g/dl for women and Hb < 14.3 g/dl for men) and without (as 174 
Hb < 12 g/dl for women and Hb < 13 g/dl for men) adjustment of 1.3 g/dl for elevation of 2500 m. (The unadjusted reference is likely 175 
more appropriate for the Mosuo, as high-altitude adapted Tibetans have been found to have only slightly elevated Hb compared to 176 
those at sea level.) Iron deficiency was defined differently in CHNS and the Mosuo datasets: Unlike most biomarkers, sTfR 177 
measurement methods can generate tremendously different values (World Health Organization, 2014), and cutpoints are specific to 178 
analysis method. sTfR in CHNS was evaluated with nephelometry (Siemens BNP), rather than enzyme immunoassay, as was used 179 
among the Mosuo. Thus, iron deficiency was defined as sTfR > 1.76 mg/l in CHNS and sTfR ≥ 8.3 mg/l among the Mosuo. sTfR was 180 
also evaluated as a continuous variable, as was CRP. Body mass index (BMI) was calculated as weight (kg)/height (m)2, and BMI was 181 
evaluated as a continuous variable.  182 
For optimal comparisons to the Mosuo sample, we limited analysis of the CHNS dataset to ethnic Han individuals age 16 y or 183 
older. We calculated age- and sex-standardized prevalences of hypertension and diabetes for all three samples (Mosuo, all Han, rural 184 
Hunan Han) by applying Mosuo and rural Hunan Han prevalences in age strata to the Han population’s age structure, stratified by sex.  185 
 Predictors of hypertension and associations between diabetes and anemia were described with logistic regression using R 3.5.1 186 
(R Foundation for Statistical Computing). Models were constructed separately for the Mosuo and the CHNS datasets. Associations 187 
between hypertension and known risk factors (age, sex, diabetes, BMI, CRP, smoking) were modeled for all three samples. Predicted 188 
probabilities for the Mosuo sample were calculated from both the rural Hunan Han model and the Mosuo model and compared. 189 
Associations between diabetes and anemia were modeled for all three samples. Known anemia risk factors including smoking, sex, 190 
age, sTfR, CRP, and BMI, which were also likely to be associated with diabetes or HbA1c test results, were included as control 191 
variables. Participant’s province was controlled in all models of the larger CHNS Han sample and field season (2018 vs. 2017) was 192 
controlled in all models of the Mosuo sample. Limited access to health care and limited communication in the healthcare setting 193 
among the Mosuo made it difficult for participants to accurately describe their current medications and co-morbid conditions, so we 194 
excluded these additional potential confounders from our analyses. 195 
 196 
Results 197 
Characteristics of the samples are shown in Table 2. As predicted, although hypertension was common among all groups, it 198 
was substantially less common among the Mosuo than either comparison group of Han (Table 3, Table 4). Diabetes was also common 199 
among all groups, with a higher prevalence among the Mosuo (Supplemental Information, Table S1).  200 
We compared predicted probabilities of hypertension from logistic regression models to assess whether Mosuo had different 201 
risk for hypertension given their values for known hypertension risk factors. Logistic regression models of hypertension 202 
(Supplemental Information, Tables S2 and S3) predicted substantially lower probabilities of hypertension when fit to the Mosuo 203 
sample than the rural Hunan Han sample (Figure 1). Comparison of these probabilities suggests that the Mosuo’s observed risk factors 204 
(age, sex, BMI, CRP, and smoking) should have resulted in a higher prevalence of hypertension than we observed if they were indeed 205 
similar to Hunan Han in hypertension risk. Specifically, the predicted probabilities of hypertension differed by 0.246 (95% CI: 0.214, 206 
0.278) between models. The mean p(hypertension) for Mosuo from the model fit to Mosuo was 0.328; the mean p(hypertension) for 207 
Mosuo from the model fit to rural Hunan Han was 0.574 (t=-14.911; df=628.19; p < 0.0001).  208 
As predicted, diabetes was positively associated with anemia among the Han (OR=1.291, ß=0.256, 95% CI=-0.004, 0.507 for 209 
all Han; OR=2.226, ß=0.800, 95% CI=-0.083, 1.644 for rural Hunan Han), but not among the Mosuo (OR= 1.341, ß=0.293, 95% CI=-210 
0.792, 1.284; Table 4 and Supplemental Information Tables S4 and S5). Comparison of the regression coefficients (Figure 2) and 211 
predicted probabilities of anemia (Figure 3) show that Mosuo were distinct in that diabetes was not associated with anemia.  212 
 213 
Discussion 214 
The low rates of hypertension and diabetes-associated anemia we observed are notable, given that Mosuo are undergoing rapid 215 
market integration, with concomitant increasing risk for hypertension, diabetes, and other chronic diseases. We postulate that Tibetan 216 
Plateau adaptations to high altitude that increase blood flow and uncouple erythropoiesis regulation from hypoxia, enhancing oxygen 217 
delivery to tissues without dramatic increases in red blood cell production, protect Mosuo against hypertension and diabetes-218 
associated anemia in an increasingly diabetogenic and obesogenic environment.  219 
Our study design is subject to some limitations: The sampling strategy limits generalizability, as the Mosuo sample was not 220 
selected at random from among the entire Mosuo population, so, although we do not suspect any systematic biasing in the sample 221 
given the recruitment strategy, the fairly high rates of diabetes we observed (substantially higher than among Tibetans (Wang et al., 222 
2017), for example) must nonetheless be interpreted with caution. In addition, relying on CHNS data to characterize hypertension risk 223 
factors and associations between diabetes and anemia among the Han precluded a comparison of our Mosuo sample to Han living at a 224 
comparable altitude (~2600 m), nor do we have a sample of Mosuo living at low altitude. It is thus possible that the lower rates of 225 
hypertension and diabetes-associated anemia we observed among the Mosuo are attributable to lifelong residence at high altitude (e.g., 226 
developmental adaptations to hypoxia), rather than to Tibetan-type genetic adaptations to altitude. However, genetic adaptations to 227 
altitude among Tibetan Plateau populations predict our findings in ways that developmental adaptations, such as increased lung 228 
volume and alveolar area, do not (Frisancho, 1977; Garruto et al., 2003).  229 
The Mosuo’s relatively low risk for hypertension suggests that Tibetan Plateau adaptations, such as enhanced vasodilation and 230 
dense capillary networks, may work not only to increase oxygen delivery to tissues, but also to mitigate the hypertensive effects of 231 
high-altitude hypoxia. It is unlikely that this observation could be attributed to better care for hypertension among the Mosuo (e.g., via 232 
medication), for whom access to medical care remains limited. This pattern was obscured in previous research among Tibetans (Aryal 233 
et al., 2016; Mingji et al., 2015; Norboo et al., 2015; Sun, 1986), which was conducted at generally higher elevations and could not 234 
adequately control for differences in lifestyle between Tibetans and comparison groups. Our work suggests that lower risk for 235 
hypertension may be an additional feature of Tibetan Plateau adaptations to high altitude.  236 
The Mosuo’s low risk for diabetes-associated anemia—despite high rates of diabetes—is consistent with evidence that 237 
erythropoietin regulation differs in fundamental ways between Himalayan populations and the Han, bolstering the emerging 238 
understanding that blunted erythropoietic responses, due to changes in the HIF pathway, characterize Tibetan Plateau adaptations to 239 
high altitude (Beall et al., 2010; Bigham & Lee, 2014). 240 
Our findings also suggest that chronic diseases may provide an important source of information for human high-altitude 241 
adaptation research. For example, although the high-altitude adaptations that are best understood involve systems that deliver oxygen 242 
to tissues, it is likely that aspects of metabolism are involved in adaptation to high altitude as well—possibly as a means to conserve 243 
the scarce resource of oxygen, or to divert it differently during exertion (Bigham & Lee, 2014). Genes involved in metabolism were 244 
among those identified as under selective pressure in Himalayan high-altitude populations (Arciero et al., 2018; Bigham & Lee, 2014). 245 
This raises the possibility that unique characteristics of diabetes epidemiology, progression, or complications could be identified in 246 
high-altitude-adapted populations, which could provide clues to ways in which positive selection on metabolism-related genes 247 
(Arciero et al., 2018; Horscroft et al., 2017) may have enhanced high-altitude function. 248 
The study of interactions between high-altitude adaptations and chronic diseases is likely to become increasingly important as 249 
market integration affects more such populations globally. Our evidence suggests that Tibetan Plateau adaptations lower risk for 250 
hypertension and diabetes-associated anemia; however, the possibility also exists for these adaptations to increase risk or complicate 251 
other chronic diseases. Further, differences in adaptations to hypoxic stress across high-altitude regions may dramatically affect high-252 
altitude adapted populations’ experience of chronic disease. Our findings likely do not apply to high-altitude-adapted populations of 253 
the Andean Plateau or Ethiopian Highlands, whose adaptations differ in key ways (Beall, 2006); though, intriguingly, at least some 254 
Andean natives have strikingly low blood pressure (Toselli, Tarazona‐Santos, & Pettener, 2001). As chronic diseases like 255 
hypertension and diabetes continue to grow as global health concerns, it is thus important to investigate how risk for chronic disease 256 
may be affected by highly localized genetic adaptation to the environment.  257 
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Supplemental Information 393 
Table S1. Age-standardized prevalences (per 1000) of diabetes for Mosuo, rural Hunan Han, and all Han >16 years of age 
 
Mosuo Rural Hunan Han All Han 
 Crude Standardized* 95% CI Crude Standardized* 95% CI Crude 95% CI 
         
Females 194.3 194.7 138.8, 285.7 69.0 69.9 43.8, 107.4 69.6 60.1, 80.1 
Males 124.0 125.0 69.9, 207.1 37.9 38.1 19.0, 69.1 73.0 62.7, 84.6 
*Prevalences were standardized to the age structure observed among all Han participants in CHNS. Differences should be 
interpreted with caution given small samples in some age-sex bins for the Mosuo and rural Hunan Han.  
394 
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Table S2. Logistic regression models of risk factors for hypertension among Han > 16 years old. 395 
 
All CHNS Han (n=6548) Rural Hunan Han (n=503) 
  OR ß 95% CI p OR ß 95% CI p 
         
Intercept  -5.41 -5.89,  -4.94 <0.001  -6.93  -8.84, -5.14 <0.001 
Diabetes 1.30 0.264 0.0411, 0.493 0.022 1.11 0.105  -0.816, 1.13 0.830 
Current smoker 0.954 -0.05 -0.206, 0.111 0.557 0.462 -0.771  -1.40, -0.160 0.015 
Female sex 0.580 -0.544 -0.686, -0.403 <0.001 0.450 -0.797  -1.38, -0.231 0.007 
Age in years 1.04 0.04 0.0399, 0.0476 <0.001 1.07 0.0685  0.0534, 0.0846 <0.001 
C-reactive 
protein (CRP) 
1.17 0.160 0.143, 0.178 0.921 0.960 -0.0404  -0.0943, 0.00746 0.113 
Body mass 
index (BMI) 
0.976 -0.02 -0.303, 0.256 <0.001 1.22 0.198  0.131, 0.268 <0.001 
Province           
Guangxi (Ref) 
   
 
     
Guizhou 0.976 -0.0241 -0.303, 0.256 0.866 
     
Heilongjiang 4.31 1.46 -0.466, 4.46 0.199 
     
Henan 1.57 0.450 0.245, 0.655 <0.001 
     
Hubei 0.844 -0.170 -0.374, 0.0334 0.101 
     
Hunan 1.07 0.0686 -0.135, 0.272 0.508 
     
Jiangsu 1.24 0.215 0.0214, 0.409 0.030 
     
Liaoning 1.95 0.670 0.430, 0.913 <0.001 
     
Shandong 1.76 0.563 0.353, 0.774 <0.001      
          
  396 
 28 
Table S3: Logistic regression model of risk factors for 397 
hypertension among Mosuo (N = 310) >16 years old. 398 
  OR ß 95% CI p 
Intercept  -7.20 -9.76, -4.83 <0.001 
Diabetes 1.31 0.270 -0.415, 0.943 0.434 
Current smoker 0.762 -0.272 -1.10, 0.556 0.518 
Female sex 1.36 0.304 -0.410, 1.05 0.411 
Age in years 1.06 0.0614 0.0403, 0.0840 <0.001 
C-reactive 
protein (CRP) 
0.960 -0.0408 -0.171, 0.0488 0.448 
Body mass index 
(BMI) 
1.14 0.134 0.0606, 0.210 <0.001 
Field season 
(2018) 
1.06 0.0630 -0.456, 0.588 0.813 
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Table S4. Logistic regression models of risk factors for anemia among Han >16 years old.  400 
  All CHNS Han (n=7504) Rural Hunan Han (n=608) 
 OR ß           95% CI p OR ß 95% CI p 
         
Intercept  -2.868 -2.868, 0.030 <0.001  -2.098 -4.009, -0.210 0.030 
Diabetes 1.291 0.256 0.256, 0.996 0.0494 2.226 0.800 -0.083, 1.644 0.067 
Current smoker 0.715 -0.336 -0.336, 0.567  <0.001 0.528 -0.638 -1.446, 0.153 0.115 
Female 1.818 0.598 0.598, 1.516 <0.001 1.885 0.634 0.044, 1.270 0.042 
Age (years) 1.022 0.022 0.022, 1.018 <0.001 1.026 0.026 0.011, 0.041 <0.001 
Soluble transferrin 
receptor (sTfR) 
3.225 1.171 1.171, 2.882  <0.001 2.692 0.990 0.597, 1.408 <0.001 
C-reactive 
protein (CRP) 
1.005 0.005 0.005, 0.999 0.158 1.024 0.024 -0.032, 0.074 0.361 
Body mass index 
(BMI) 
0.902 -0.104 -0.104, 0.881  <0.001 0.890 -0.116 -0.193, -0.043 0.002 
Province           
Guangxi (Ref)      
     
Guizhou 0.535 -0.625 -0.625, 0.342 0.005 
     
Heilongjiang 0.650 -0.431 -0.431, 0.467 0.010 
     
Henan 1.195 0.178 0.178, 0.898 0.220 
     
Hubei 1.830 0.604 0.604, 1.400 <0.001 
     
Hunan 1.866 0.624 0.624, 1.443 <0.001 
     
Jiangsu 1.096 0.092 0.092, 0.835 0.508 
     
Liaoning 0.545 -0.608 -0.608, 0.373 0.001 
     
Shandong 0.752 -0.285 -0.285, 0.549 0.073           
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Table S5. Logistic regression models of risk factors for anemia among Mosuo > 16 years old (N = 310).  402 
 Anemia1 Altitude-adjusted anemia2 
  OR ß      95% CI p OR ß      95% CI p 
         
Intercept  -2.21 -6.29, 1.38 0.246  0.497 -1.79, 2.80 0.670 
Diabetes 1.34 0.293 -0.792, 1.28 0.575 0.949 -0.0521 -0.818, 0.686 0.891 
Current smoker  0.523 -0.649 -3.71, 1.34 0.585 0.907 -0.0980 -1.11, 0.910 0.847 
Female sex 14.9 2.70 0.856, 5.77 0.021 5.36 1.68 0.843, 2.62 <0.001 
Age in years 0.972 -0.0284 -0.0604, 0.00199 0.073 0.988 -0.0116 -0.0318, 0.00817 0.251 
Soluble transferrin 
receptor (sTfR) 
1.32 0.279 0.105, 0.465 0.002 1.08 0.0724 -0.0660, 0.211 0.302 
C-reactive 
protein (CRP) 
1.00 -0.00431 -0.240, 0.117 0.958 0.962 -0.0383 -0.174, 0.0513 0.479 
Body mass index 
(BMI) 
0.918 -0.0851 -0.201, 0.0226 0.133 0.926 -0.0766 -0.153, -0.00287 0.044 
Field season 
(2018) 
0.267 -1.32 -2.23, -0.469 0.003 0.348 -1.05 -1.65, -0.476 <0.001 
         
1 Hb < 12 g/dl for females and Hb < 13 g/dl for males 403 
2 Hb < 13.3 g/dl for females and Hb < 14.3 g/dl for males 404 
 405 
 406 
